SS Innovations International (NASDAQ: SSII) Reports 79% Growth in SSi Mantra Procedures, Expands Global Reach

At a glance

Company: SS Innovations International, Inc.
Ticker: NASDAQ: SSII
Announcement: Expansion

Key figures

Cumulative procedures as of Sept. 8, 2026: 14,103
Increase in procedures from year-end 2025: 79%
Installed systems: 238
Increase in installed base: 42%
Countries with installations: 12
Physicians trained: approximately 1,500

Products and programs

SSi Mantra surgical robotic system
SSi Mudra surgical instruments

SS Innovations International (NASDAQ: SSII) provided an update on the continued expansion and utilization of its SSi Mantra surgical robotic system, reporting 14,103 cumulative procedures as of Sept. 8, 2026, up 79% from 7,885 at year-end 2025, while its installed base increased 42% to 238 systems from 168. The SSi Mantra is now installed across 12 countries, approximately 1,500 physicians have been trained on the platform and the system has been used for more than 170 types of surgical procedures. Recent international milestones include the launch of robotic cardiac surgery in Colombia, installation of the first SSi Mantra in Sri Lanka and the first telesurgery within the Philippines.

SS Innovations also highlighted 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of Aug. 31, including a more than 13,600-mile telesurgery between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India. Looking ahead, the company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027 and believes European Union CE marking certification can be obtained by year-end 2026.

To view the full report, visit https://ibn.fm/DJILj

About SS Innovations

SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

Corporate Communications

IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]

In brief

SS Innovations International reported growth in use of its SSi Mantra surgical robotic system, with 14,103 cumulative procedures recorded as of Sept. 8, 2026. The company says that figure was 79% above its year-end 2025 total, while its installed base reached 238 systems, a 42% increase. The platform is installed in 12 countries, and about 1,500 physicians have received training, according to the company. Recent milestones include robotic cardiac surgery in Colombia, an installation in Sri Lanka and a telesurgery in the Philippines. The company also reported pediatric operations and telesurgeries, including a procedure connecting Colombia and India. SS Innovations expects the FDA’s review of its 510(k) submission to conclude by the end of the first quarter of 2027 and says it believes EU CE marking could be secured by year-end 2026.

Key takeaways

The company reported 14,103 cumulative SSi Mantra procedures as of Sept. 8, 2026, up 79% from year-end 2025.
Its installed base reached 238 systems, and the platform is now present in 12 countries.
Recent milestones include robotic cardiac surgery in Colombia, an installation in Sri Lanka and telesurgery in the Philippines.
SS Innovations expects FDA review of its 510(k) submission by the end of the first quarter of 2027.

SEC filings

Earlier from SS Innovations

Back to News Center